CA2798419C - 8-hydroxy-quinoline derivatives - Google Patents

8-hydroxy-quinoline derivatives Download PDF

Info

Publication number
CA2798419C
CA2798419C CA2798419A CA2798419A CA2798419C CA 2798419 C CA2798419 C CA 2798419C CA 2798419 A CA2798419 A CA 2798419A CA 2798419 A CA2798419 A CA 2798419A CA 2798419 C CA2798419 C CA 2798419C
Authority
CA
Canada
Prior art keywords
group
trifluoromethyl
optionally substituted
meta
ortho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2798419A
Other languages
English (en)
French (fr)
Other versions
CA2798419A1 (en
Inventor
Laszlo Puskas
Csaba Szabo
Ivan Kanizsai
Mario Gyuris
Ramona Madacsi
Bela Ozsvari
Liliana Feher
Gabor Tamas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
"AVIDIN" KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG
Soneas Kutato Korlatolt Felelossegu Tarsasag
Original Assignee
"AVIDIN" KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG
Soneas Kutato Korlatolt Felelossegu Tarsasag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by "AVIDIN" KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG, Soneas Kutato Korlatolt Felelossegu Tarsasag filed Critical "AVIDIN" KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG
Publication of CA2798419A1 publication Critical patent/CA2798419A1/en
Application granted granted Critical
Publication of CA2798419C publication Critical patent/CA2798419C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CA2798419A 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives Active CA2798419C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives
HUP1000243 2010-05-06
PCT/HU2011/000043 WO2011148208A1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives

Publications (2)

Publication Number Publication Date
CA2798419A1 CA2798419A1 (en) 2011-12-01
CA2798419C true CA2798419C (en) 2021-01-05

Family

ID=89989711

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2798419A Active CA2798419C (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives

Country Status (21)

Country Link
US (1) US8871937B2 (cg-RX-API-DMAC7.html)
EP (1) EP2566849B1 (cg-RX-API-DMAC7.html)
JP (1) JP5812541B2 (cg-RX-API-DMAC7.html)
KR (1) KR101837974B1 (cg-RX-API-DMAC7.html)
CN (1) CN102985407B (cg-RX-API-DMAC7.html)
AU (1) AU2011256989B2 (cg-RX-API-DMAC7.html)
CA (1) CA2798419C (cg-RX-API-DMAC7.html)
CY (1) CY1122426T1 (cg-RX-API-DMAC7.html)
DK (1) DK2566849T3 (cg-RX-API-DMAC7.html)
EA (1) EA021026B1 (cg-RX-API-DMAC7.html)
ES (1) ES2761832T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20192278T1 (cg-RX-API-DMAC7.html)
HU (2) HUP1000243A2 (cg-RX-API-DMAC7.html)
MX (1) MX337999B (cg-RX-API-DMAC7.html)
NZ (1) NZ603967A (cg-RX-API-DMAC7.html)
PL (1) PL2566849T3 (cg-RX-API-DMAC7.html)
PT (1) PT2566849T (cg-RX-API-DMAC7.html)
RS (1) RS59678B1 (cg-RX-API-DMAC7.html)
SI (1) SI2566849T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900710T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011148208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500098A2 (hu) 2015-03-09 2016-09-28 Avidin Kft 8-hidroxikinolin származékok új enantiomerjei és szintézisük
EP3361871A4 (en) * 2015-10-12 2019-06-26 Health Research, Inc. PROCESS FOR INDUCING APOPTOSIS IN CANCER CELLS
CN105367553A (zh) * 2015-12-04 2016-03-02 广东工业大学 一种他克林-8-羟（胺）基喹啉衍生物及其应用
HUP1600234A2 (en) 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives
WO2024073624A2 (en) * 2022-09-28 2024-04-04 The Research Foundation For The State University Of New York Antiproliferative betti bases and prodrugs thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015179A1 (en) 1997-09-25 1999-04-01 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
JP2002501018A (ja) 1998-01-26 2002-01-15 マイトコー ミトコンドリア関連疾患を処置するためのミトコンドリア保護剤
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
KR20020033777A (ko) 1999-08-27 2002-05-07 추후보정 치환된 α-히드록시 산 카스파제 억제제 및 이의 용도
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
WO2002030411A2 (en) 2000-10-13 2002-04-18 Johns Hopkins University Treatment of apoptotic cell death
US6552076B2 (en) 2000-12-15 2003-04-22 Mitokor Compounds for altering mitochondrial function and cellular responses
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
CA2452005C (en) 2001-07-10 2011-03-15 Idec Pharmaceutical Corporation Inhibition of apoptosis process and improvement of cell performance
DE10144153A1 (de) 2001-09-07 2003-03-27 Newfrey Llc Halteclip mit versetzten Rastfingern
AU2003211102B2 (en) 2002-02-13 2010-03-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
US7217709B2 (en) 2003-02-28 2007-05-15 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP4824566B2 (ja) 2003-05-28 2011-11-30 エーザイ インコーポレーテッド Ｐａｒｐを阻害するための化合物、方法、および医薬組成物
NZ549393A (en) 2004-01-23 2009-07-31 Cornell Res Foundation Inc Methods for reducing oxidative damage
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CN101309908A (zh) 2005-11-15 2008-11-19 艾博特公司 作为有效parp抑制剂的取代的1h-苯并咪唑-4-甲酰胺化合物
US7528174B2 (en) 2006-01-06 2009-05-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Selective targeting agents for mitochondria
CN101611009A (zh) * 2006-07-25 2009-12-23 伊维沃制药股份有限公司 喹啉衍生物
US8609649B2 (en) * 2007-03-20 2013-12-17 Brandeis University Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
CA2687187A1 (en) 2007-05-25 2008-12-18 Burnham Institute For Medical Research Inhibitors of thapsigargin-induced cell death
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
US10301265B2 (en) * 2008-05-28 2019-05-28 Virginia I. Roxas-Duncan Small molecule inhibitors of botulinum neurotoxins
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
AU2011204368B2 (en) * 2010-01-06 2014-11-27 Joseph P. Errico Methods and compositions of targeted drug development

Also Published As

Publication number Publication date
HUP1000243A2 (en) 2012-01-30
WO2011148208A1 (en) 2011-12-01
PT2566849T (pt) 2020-01-06
CA2798419A1 (en) 2011-12-01
US20130131096A1 (en) 2013-05-23
EA201270787A1 (ru) 2013-04-30
PL2566849T3 (pl) 2020-03-31
AU2011256989A1 (en) 2013-01-10
HU1000243D0 (en) 2010-06-28
SMT201900710T1 (it) 2020-01-14
CN102985407A (zh) 2013-03-20
HRP20192278T1 (hr) 2020-03-06
DK2566849T3 (da) 2020-01-02
CN102985407B (zh) 2015-09-09
HUE050886T2 (hu) 2021-01-28
NZ603967A (en) 2014-06-27
SI2566849T1 (sl) 2020-02-28
EA021026B1 (ru) 2015-03-31
RS59678B1 (sr) 2020-01-31
JP5812541B2 (ja) 2015-11-17
AU2011256989B2 (en) 2014-08-21
KR101837974B1 (ko) 2018-03-13
EP2566849A1 (en) 2013-03-13
JP2013525473A (ja) 2013-06-20
KR20130029772A (ko) 2013-03-25
MX2012012883A (es) 2013-03-20
CY1122426T1 (el) 2021-01-27
MX337999B (es) 2016-03-30
US8871937B2 (en) 2014-10-28
ES2761832T3 (es) 2020-05-21
EP2566849B1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
CA3029857C (en) Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
JP5236293B2 (ja) Ｘｉａ因子阻害剤としての置換ビアリール化合物
CN108524482B (zh) 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
RU2724333C2 (ru) Производное 1,3,5-триазина и способ его применения
JP7728989B2 (ja) 三環式ｐａｒｐ１阻害剤及びその使用
WO2013078771A1 (zh) 一种多聚（adp-核糖）聚合酶抑制剂
CA2798419C (en) 8-hydroxy-quinoline derivatives
KR20170095964A (ko) Hdac1/2 억제제로서 피페리딘 유도체
JP2022528042A (ja) アミド類化合物の調製方法及びその医薬分野の使用
CA2748124A1 (en) Ppar agonist compositions and methods of use
JPWO2016148114A1 (ja) 酸化ストレス誘導神経細胞死抑制化合物
KR20160003196A (ko) ＂니코틴아미드 포스포리보실트랜스퍼라제의 억제제, 조성물, 제품 및 그의 용도＂
JP7185631B2 (ja) 抗線維化化合物
KR20100132553A (ko) 신규한 ｎ-(2-아미노-페닐)-아크릴아미드
JP2018087173A (ja) 悪性脳腫瘍治療薬
AU2017341020B2 (en) Urea derivative
US20110098304A1 (en) Small molecule inhibitors of PARP activity
KR20240057820A (ko) 신규 피라졸로-옥소티아졸리딘 유도체 및 이를 포함하는 알칼리성 포스파타제 억제제
JP4431796B2 (ja) 新規な抗マラリア剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160412